NASDAQ:INVA - Innoviva Stock Price, Price Target & More

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva (NASDAQ:INVA) released its quarterly earnings results on Thursday, April, 26th. The biotechnology company reported $0.27 EPS for the quarter, missing the Zacks' consensus estimate of $0.50 by $0.23. The biotechnology company earned $52.40 million during the quarter, compared to the consensus estimate of $71.84 million. Innoviva had a net margin of 64.11% and a negative return on equity of 63.57%. The company's revenue for the quarter was up 29.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.19 EPS. View Innoviva's Earnings History.

Innoviva is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Innoviva.

6 brokers have issued 12-month target prices for Innoviva's stock. Their predictions range from $8.00 to $16.00. On average, they expect Innoviva's share price to reach $13.20 in the next year. View Analyst Ratings for Innoviva.

Innoviva saw a drop in short interest in April. As of April 30th, there was short interest totalling 11,842,171 shares, a drop of 11.3% from the April 13th total of 13,344,078 shares. Based on an average daily trading volume, of 1,262,701 shares, the short-interest ratio is currently 9.4 days. Approximately 17.7% of the shares of the company are short sold.

Some companies that are related to Innoviva include Ionis Pharmaceuticals (IONS), Catalent (CTLT), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY) and Ultragenyx Pharmaceutical (RARE).

News headlines about INVA stock have trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Innoviva earned a coverage optimism score of 0.09 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.37 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Innoviva's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.68%), Dimensional Fund Advisors LP (1.69%), First Eagle Investment Management LLC (1.34%), Northern Trust Corp (1.01%), UBS Group AG (0.70%) and Victory Capital Management Inc. (0.63%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.

INVA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., JPMorgan Chase & Co., Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Smith Asset Management Group LP, Systematic Financial Management LP, Camarda Financial Advisors LLC and Northern Trust Corp. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie, Michael W Aguiar and Theodore J Jr Witek. View Insider Buying and Selling for Innoviva.

INVA stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Dimensional Fund Advisors LP, PNC Financial Services Group Inc., WINTON GROUP Ltd, Millennium Management LLC, Hsbc Holdings PLC, Algert Global LLC and Hussman Strategic Advisors Inc.. View Insider Buying and Selling for Innoviva.

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of INVA stock can currently be purchased for approximately $14.47.

Innoviva has a market capitalization of $1.49 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.

Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]